Navigation Links
VirtualScopics Schedules Second Quarter 2010 Earnings Announcement
Date:7/26/2010

ROCHESTER, N.Y., July 26 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP), a leading provider of quantitative imaging for clinical trials, announced today that before the market opens on Thursday, August 12, 2010 it will release its second quarter 2010 financial results. The company will host a conference call that morning at 11:00 a.m. EDT.

VirtualScopics' President and Chief Executive Officer, Jeff Markin, and Chief Business and Financial Officer, Molly Henderson, will provide a business update and discuss the company's results for the quarter ended June 30, 2010 during the conference call.

Interested participants should call 877-407-8035 when calling within the United States or +1 201 689 8035 when calling internationally.  This call can also be accessed at www.virtualscopics.com and will be available for 30 days after the call.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development.  VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images.  In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster.  For more information about VirtualScopics, visit www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the backlog and new customer awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2009 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to awards of contracts currently under negotiation, the risk that they may not get signed.  Other risks include the company's dependence on its largest customers and risks of contract performance. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

CONTACT:

Tim Ryan

The Shoreham Group LLC

80 Eighth Ave, Ste 1107

New York, NY 10011

+1 212 242 7777 Direct

+1 646 342 6199 Cell

+1 484 377 9916 Fax

tryan@shorehamgroupllc.com 

www.shorehamgroupllc.com 


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
2. VirtualScopics Project Balance Exceeds a Record $35 Million
3. VirtualScopics to Present at the 8th Annual Bio Investor Forum
4. VirtualScopics Schedules Third Quarter 2009 Earnings Announcement
5. VirtualScopics to Present at the Upcoming OneMedPlace Investment Conference
6. VirtualScopics Receives Issuance in Japan of Prominent Patent
7. VirtualScopics Added to Russell Microcap Index
8. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
9. Wyeth Applauds Six Countries Across Europe, and the Middle East, That Recently Announced the Inclusion of the 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Their Immunization Schedules
10. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
11. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
(Date:5/26/2016)... India , May 26, 2016 ... drugs market growth is the emergence of new treatments. ... astaxanthin therapies for osteoarthritis treatment. The therapy is expected ... Moreover, Arthritis Research UK is conducting studies to develop ... arcOGEN study, where the genes involved in osteoarthritis are ...
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer of ... was more than humbled by customer demand over the Mother’s Day Weekend promotion. So ... Now that Bunion Bootie has completely replenished its inventory levels, it hopes to continue ...
(Date:5/26/2016)... ... 2016 , ... The introduction of our professional athletes coincides with the company’s ... , “We are proud to introduce Meghan Klingenberg, defender and World Champion with ... wide receiver for Los Angeles who was a second round selection in the 2012 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel Film ... FCPX. , "This new layered style transition tool will keep a consistent flow to ... of Pixel Film Studios. , TranSweep is an all new layered style transition ...
(Date:5/26/2016)... ... 26, 2016 , ... According to the Webster’s dictionary, a hippie is defined ... products, one company is going against the norm with a line of all-natural skincare ... in the green space is proud to announce its latest retail partnership with the ...
Breaking Medicine News(10 mins):